Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.

Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound ...

The Trump administration this month scrapped a Biden-era proposal that would have required state Medicaid programs and ...

Novo Nordisk, the maker of Wegovy, announced exclusively on " Good Morning America " Tuesday that the medication will soon be available for purchase through the telehealth companies Ro, Hims and ...

Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...

As of last week, Chris Klomp is in charge of the Center for Medicare. Unlike predecessors, he’s not a policy wonk. Klomp was ...

Medicare coverage of obesity medications could drive a substantial rise in healthcare spending, according to a new study. A microsimulation model published in JAMA Health Forum projected that Medicare ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Novo Nordisk partners with telehealth ...

Novo Nordisk has teamed up with Hims & Hers Health, LifeMD and Ro for cash-paying patients to access Wegovy injection 2.4 mg ...

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; Novo’s has fallen by as much (see chart 2). Lilly’s edge rests on a more ...

CVS Health topped Q1 estimates with $94.59 billion in revenue and raised 2025 EPS outlook to $6.00–$6.20 amid strong Medicare ...